FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022755629> ?p ?o ?g. }

• W2022755629 endingPage "110" @default.
• W2022755629 startingPage "103" @default.
• W2022755629 abstract "Choosing effective therapy for patients with malignant pheochromocytoma or paraganglioma (PPGL) is problematic and none of the options are curative. Although combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) is an established treatment option, only a limited number of case series have been reported in the literature. To determine the efficacy of CVD in patients treated at Tokyo Women's Medical University. Retrospective review of patients treated with CVD between 1989 and 2012 was conducted. Demographics, clinical presentation, imaging, and laboratory reports were reviewed and analyzed. Efficacy of CVD was ascertained from the biochemical and tumor responses. Twenty-three patients fulfilled study criteria and 6 of these were excluded due to inadequate follow-up or discontinuance by poor general condition or adverse effects. Thus, 17 cases were included in the study. The age and duration of the disease before initiation of CVD were 54.7 ± 12.0 years and 9.1 ± 8.1 years, respectively. The follow-up period after initiation of CVD ranged from 12 to 192 months (median, 60 months). Complete or partial biochemical and/or partial tumor response was achieved in 47.1 % (responders). No significant biochemical or tumor response was seen in 23.5 % and deterioration in biochemical and tumor outcomes was seen in 29.4 % (non-responders). No patient showed complete biochemical and tumor responses. In responders, these effects were documented within 4 months after initiation of CVD with a progression-free survival of 31 to 60 months (median, 40 months). Age at the first diagnosis with PPGL was younger (P < 0.05) and the lag time to eventual diagnosis of malignant disease was longer (P < 0.05) in responders than those in non-responders. The responders had improvements in hypertension and impaired glucose tolerance. Although CVD chemotherapy is not curative for patients with malignant PPGL, it does provide approximately half of the patients with biochemical, tumor, and hypertension benefits." @default.
• W2022755629 created "2016-06-24" @default.
• W2022755629 creator A5025921038 @default.
• W2022755629 creator A5032378287 @default.
• W2022755629 creator A5067014259 @default.
• W2022755629 creator A5075757845 @default.
• W2022755629 creator A5086656767 @default.
• W2022755629 creator A5090348913 @default.
• W2022755629 date "2013-01-30" @default.
• W2022755629 modified "2023-10-06" @default.
• W2022755629 title "Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma" @default.
• W2022755629 cites W1583414463 @default.
• W2022755629 cites W1663742962 @default.
• W2022755629 cites W1966973785 @default.
• W2022755629 cites W1992104765 @default.
• W2022755629 cites W2006431368 @default.
• W2022755629 cites W2056251311 @default.
• W2022755629 cites W2075128901 @default.
• W2022755629 cites W2090145664 @default.
• W2022755629 cites W2090592939 @default.
• W2022755629 cites W2091458767 @default.
• W2022755629 cites W2095058352 @default.
• W2022755629 cites W2107966316 @default.
• W2022755629 cites W2126200526 @default.
• W2022755629 cites W2144445356 @default.
• W2022755629 cites W2159630723 @default.
• W2022755629 cites W2163345744 @default.
• W2022755629 cites W2167405406 @default.
• W2022755629 cites W2167466716 @default.
• W2022755629 cites W4248473291 @default.
• W2022755629 doi "https://doi.org/10.1007/s12672-013-0133-2" @default.
• W2022755629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23361939" @default.
• W2022755629 hasPublicationYear "2013" @default.
• W2022755629 type Work @default.
• W2022755629 sameAs 2022755629 @default.
• W2022755629 citedByCount "59" @default.
• W2022755629 countsByYear W20227556292013 @default.
• W2022755629 countsByYear W20227556292014 @default.
• W2022755629 countsByYear W20227556292015 @default.
• W2022755629 countsByYear W20227556292016 @default.
• W2022755629 countsByYear W20227556292017 @default.
• W2022755629 countsByYear W20227556292018 @default.
• W2022755629 countsByYear W20227556292019 @default.
• W2022755629 countsByYear W20227556292020 @default.
• W2022755629 countsByYear W20227556292021 @default.
• W2022755629 countsByYear W20227556292022 @default.
• W2022755629 countsByYear W20227556292023 @default.
• W2022755629 crossrefType "journal-article" @default.
• W2022755629 hasAuthorship W2022755629A5025921038 @default.
• W2022755629 hasAuthorship W2022755629A5032378287 @default.
• W2022755629 hasAuthorship W2022755629A5067014259 @default.
• W2022755629 hasAuthorship W2022755629A5075757845 @default.
• W2022755629 hasAuthorship W2022755629A5086656767 @default.
• W2022755629 hasAuthorship W2022755629A5090348913 @default.
• W2022755629 hasBestOaLocation W20227556291 @default.
• W2022755629 hasConcept C126322002 @default.
• W2022755629 hasConcept C141071460 @default.
• W2022755629 hasConcept C143998085 @default.
• W2022755629 hasConcept C167135981 @default.
• W2022755629 hasConcept C197934379 @default.
• W2022755629 hasConcept C2776694085 @default.
• W2022755629 hasConcept C2776734335 @default.
• W2022755629 hasConcept C2776755627 @default.
• W2022755629 hasConcept C2777658100 @default.
• W2022755629 hasConcept C2779429289 @default.
• W2022755629 hasConcept C2779512018 @default.
• W2022755629 hasConcept C2780964509 @default.
• W2022755629 hasConcept C502942594 @default.
• W2022755629 hasConcept C71924100 @default.
• W2022755629 hasConceptScore W2022755629C126322002 @default.
• W2022755629 hasConceptScore W2022755629C141071460 @default.
• W2022755629 hasConceptScore W2022755629C143998085 @default.
• W2022755629 hasConceptScore W2022755629C167135981 @default.
• W2022755629 hasConceptScore W2022755629C197934379 @default.
• W2022755629 hasConceptScore W2022755629C2776694085 @default.
• W2022755629 hasConceptScore W2022755629C2776734335 @default.
• W2022755629 hasConceptScore W2022755629C2776755627 @default.
• W2022755629 hasConceptScore W2022755629C2777658100 @default.
• W2022755629 hasConceptScore W2022755629C2779429289 @default.
• W2022755629 hasConceptScore W2022755629C2779512018 @default.
• W2022755629 hasConceptScore W2022755629C2780964509 @default.
• W2022755629 hasConceptScore W2022755629C502942594 @default.
• W2022755629 hasConceptScore W2022755629C71924100 @default.
• W2022755629 hasIssue "2" @default.
• W2022755629 hasLocation W20227556291 @default.
• W2022755629 hasLocation W20227556292 @default.
• W2022755629 hasLocation W20227556293 @default.
• W2022755629 hasOpenAccess W2022755629 @default.
• W2022755629 hasPrimaryLocation W20227556291 @default.
• W2022755629 hasRelatedWork W1979285281 @default.
• W2022755629 hasRelatedWork W1995410086 @default.
• W2022755629 hasRelatedWork W2068005285 @default.
• W2022755629 hasRelatedWork W2071257112 @default.
• W2022755629 hasRelatedWork W2135683443 @default.
• W2022755629 hasRelatedWork W2392495292 @default.
• W2022755629 hasRelatedWork W2392709452 @default.
• W2022755629 hasRelatedWork W2898917781 @default.
• W2022755629 hasRelatedWork W2964822800 @default.

• next